192 results on '"Prasithsirikul, Wisit"'
Search Results
2. Comparison of the Immune Response After an Extended Primary Series of COVID-19 Vaccination in Kidney Transplant Recipients Receiving Standard Versus Mycophenolic Acid–sparing Immunosuppressive Regimen
3. Simultaneously complete but not partial taste and smell losses were associated with SARS-CoV-2 infection
4. Pharmacokinetics of Sofosbuvir/Velpatasvir and efficacy of an alternate‐day treatment in hemodialysis patients with chronic hepatitis C infection.
5. Assessment of anxiety and depression among hospitalized COVID-19 patients in Thailand during the first wave of the pandemic: a cross-sectional study
6. Clinical Characteristics of Patients Hospitalized with Coronavirus Disease, Thailand
7. Neurocognitive impairment in patients randomized to second-line lopinavir/ritonavir-based antiretroviral therapy vs. lopinavir/ritonavir monotherapy
8. Comparison of Antibody Persistence up to 6 Months after Additional Booster Vaccination with ChAdOx1 nCoV-19 Vaccine
9. Low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai adults with HIV (LASA): a randomised, open-label, non-inferiority trial
10. Benefits of Switching Mycophenolic Acid to Sirolimus on Serological Response after a SARS-CoV-2 Booster Dose among Kidney Transplant Recipients: A Pilot Study
11. Long-term outcomes of HIV-infected children in Thailand: the Thailand Pediatric HIV Observational Database
12. Chronic kidney disease incidence and survival of Thai HIV-infected patients
13. ChAdOx1 nCoV-19 Immunogenicity and Immunological Response Following COVID-19 Infection in Patients Receiving Maintenance Hemodialysis
14. Immunogenicity of ChAdOx1 nCoV-19 Booster Vaccination Following Two CoronaVac Shots in Healthcare Workers
15. Multiple clades of SARS‐CoV‐2 were introduced to Thailand during the first quarter of 2020
16. Health Utilities in Patients with HIV/AIDS in Thailand
17. Risk factors for mortality in symptomatic hyperlactatemia among HIV-infected patients receiving antiretroviral therapy in a resource-limited setting
18. Prevalence of Metabolic Syndrome Among Antiretroviral-Naive and Antiretroviral-Experienced HIV-1 Infected Thai Adults
19. Nevirapine levels after discontinuation of Rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis
20. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial
21. Clinical course and potential predictive factors for pneumonia of adult patients with Coronavirus Disease 2019 (COVID-19): A retrospective observational analysis of 193 confirmed cases in Thailand
22. Adjunctive favipiravir for severe COVID-19: a retrospective observational study of the first 41 patients in Thailand
23. Potential dual dengue and SARS-CoV-2 infection in Thailand: A case study
24. Journey of a Thai Taxi Driver and Novel Coronavirus
25. The association of anti-r-HuEpo-associated pure red cell aplasia with HLA-DRB1*09-DQB1*0309
26. Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection
27. Incidence and risk factors of nevirapine-associated skin rashes among HIV-infected patients with CD4 cell counts <250 cells/μL
28. No change in calculated creatinine clearance after tenofovir initiation among Thai patients
29. Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin
30. Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin
31. Renal impairment after switching from stavudine/lamivudine to tenofovir/lamivudine in NNRTI-based antiretroviral regimens
32. Treatment outcomes and plasma level of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who had NRTI and NNRTI failure
33. HLA-Cw*04 allele associated with nevirapine-induced rash in HIV-infected Thai patients
34. No change in calculated creatinine clearance after tenofovir initiation among Thai patients
35. A Single-Nucleotide Polymorphism in ABCC4 Is Associated with Tenofovir-Related Beta2-Microglobulinuria in Thai Patients with HIV-1 Infection
36. Chronic kidney disease incidence and survival of Thai HIV-infected patients.
37. Effect of nutritional counseling on low-density lipoprotein cholesterol among Thai HIV-infected adults receiving antiretroviral therapy
38. Risk of First-line Antiretroviral Therapy Failure in HIV-infected Thai Children and Adolescents
39. Depression and anxiety were low amongst virally suppressed, long-term treated HIV-infected individuals enrolled in a public sector antiretroviral program in Thailand.
40. Ritonavir-Boosted Lopinavir as Maintenance Monotherapy in HIV-Infected Patients Who Achieved Viral Suppression during a Second-Line Protease Inhibitor–Based Regimen
41. Polymorphisms in Fas Gene Is Associated with HIV-Related Lipoatrophy in Thai Patients
42. Effect of nutritional counseling on low-density lipoprotein cholesterol among Thai HIV-infected adults receiving antiretroviral therapy.
43. Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens
44. Effectiveness of Boosted Protease Inhibitor-Based Regimens in HIV Type 1-Infected Patients Who Experienced Virological Failure with NNRTI-Based Antiretroviral Therapy in a Resource-Limited Setting
45. Renal impairment after switching from stavudine/lamivudine to tenofovir/lamivudine in NNRTI-based antiretroviral regimens
46. The Impact of Combination Antiretroviral Therapy and its Interruption on Anxiety, Stress, Depression and Quality of Life in Thai Patients
47. HLA-Cw*04 allele associated with nevirapine-induced rash in HIV-infected Thai patients
48. Treatment outcomes and plasma level of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who had NRTI and NNRTI failure
49. Effectiveness and metabolic complications after 96 weeks of a generic fixed-dose combination of stavudine, lamivudine, and nevirapine among antiretroviral-naive advanced HIV-infected patients in Thailand: A prospective study
50. Plasma Levels, Safety, and 60-Week Efficacy of a Once-Daily Double-Boosted Protease Inhibitor Regimen of Atazanavir, Saquinavir, and Ritonavir
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.